

2.54cm or 1inch margin on all sides for the whole manuscript

Font: Time New Roman, Size: 14, Style: Bold, Small Title case (Should not be Caps), Align: Center

Simultaneous estimation of fluticasone propionate, azelastine hydrochloride, phenylethyl alcohol and benzalkonium chloride by RP-HPLC method in nasal sprays

Font: Time New Roman, Size: 12, Style: Bold, Small Title case (Should not be Caps), Align: Center

Superscript number for indicating affiliations of author and co authors

**K. Lakshmi Narasimha Rao^{*1}, K. Padmaja Reddy², K. Sudheer Babu¹,
K. Soloman Raju¹, K. Visweswara Rao², Jafer Vali Shaik²**

Asterisk (*) for the corresponding author (Should not be superscripted)

¹Department of Branded Formulations, Analytical Research & Development, Dr.Reddy's Laboratories, IPDO, Bachupally, Hyderabad- 500 072 India

²Department of Active pharmaceutical Ingredient, Analytical Research & Development, Dr.Reddy's Laboratories, IPDO, Bachupally, Hyderabad- 500 072 India

Superscript number for indicating affiliations of author and co authors

Font: Time New Roman, Size: 12, Style: Bold, Small Title case (Should not be Caps), Align: Center

* Corresponding Author

Name: Dr. K. Lakshmi Narasimha Rao

Email: klnrao@gmail.com

Contact: +91-9824526321

Fax: +91-480-3103284

Date of Submission: 15-03-2011

All fields are mandatory except Fax no.

**Font: Times New Roman, Size: 12,
Style: Bold, Caps, Align: Left**

ABSTRACT

A simple, reproducible and accurate efficient reverse phase chromatographic method was developed for simultaneous estimation of Fluticasone propionate (FLP), Azelastine Hydrochloride (AZH), Phenylethyl alcohol (PEA) and Benzalkonium chloride (BKC) in combined nasal spray preparations. Formulation

The Abstract should be minimum 150 words, not more than 300 words and unstructured. In abstract author has to include the aim, materials and methods, results and conclusion. But author should present this information without subheadings. It should be like self explanatory of entire work done by the author and co authors.

used as antihistamine-corticosteroid combination available as a metered spray formulation for nasal or intranasal administration. Chromatography was performed on a 250 mm x 4.6 mm, 5- μ m particle size, Waters Spherisorb CN column with a 55:45 (v/v) mixture of buffer and acetonitrile as a mobile phase. The detection of the combined dosage form was carried out at 215 nm and flow rate employed was 1.0 ml/min. The retention times were 3.380, 4.855, 6.647 & 10.175, 12.179 min for Phenylethyl alcohol, Fluticasone propionate, Azelastine Hydrochloride and Benzalkonium chloride (C12,C14), respectively. Linearity was established in the concentration range 70.0 to 120.0 μ g/ml for Phenyl ethyl alcohol, 14.0 to 24.0 μ g/ml for Fluticasone propionate, 39.2 to 67.2 μ g /ml for Azelastine Hydrochloride and in the range 2.8 to 4.8 μ g/ml for Benzalkonium chloride, with a correlation coefficient of 0.9961, 0.9992, 0.997 and 0.9997, respectively. The results of the analysis were validated statistically and recovery studies confirmed the accuracy and precision of the proposed method.

Keywords: Azelastine Hydrochloride; Benzalkonium chloride; Fluticasone propionate; Nasal preparations; Phenylethyl alcohol; Simultaneous estimation

Four to eight keywords should be added at the end of Abstract. Keywords should not reflect the titles. Individual keywords should be separated by (;) and ordered alphabetically.

Font: Time New Roman, Size: 12, Style: Regular, Double space, Align: Justify, Subheadings should not be Caps.

INTRODUCTION

Fluticasone propionate and Azelastine Hydrochloride Nasal Spray is an antihistamine-corticosteroid combination available as a metered spray formulation for intranasal administration. It contains azelastine hydrochloride, which is a second generation H1 receptor-antagonist with potent topical activity. Chemically it is known as 4-((4-Chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone, hydrochloride. Azelastine hydrochloride occurs as a white, almost odorless, crystalline powder with a bitter taste. It has a molecular weight of 418.37. Fluticasone propionate, a synthetic corticosteroid with anti-inflammatory properties. Chemically it is known as (6 α ,11 β -16 α ,17 β)-6,9-Difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxo-propoxy)androsta-1,4-diene-17-carbothioic acid S-(fluoromethyl) ester. Fluticasone propionate is a white to off-white powder with a molecular weight of 500.58. Benzalkonium chloride is chemically known as alkyldimethyl (phenylmethyl) ammonium chloride. Three major homologues consist of C₁₂, C₁₄ and C₁₆ straight chain alkyls. It acts as a Pharmaceutical aid (preservative), Algeside. (The Merck Index.3, 2006, British pharmacopoeia, United states pharmacopoeia, Jadwiga Dudkiewicz-Wilczynska., *et al.*, 2004; Louis-Philippe *et al.*, 2007). Phenylethyl alcohol is chemically known as 2 – phenyl ethanol. Its molecular weight is 122.16. It acts as a Pharmaceutical aid (antimicrobial). (The Merck Index.3, 2006). In this formulation FLP and AZH was drug substance where as P was excipient. The amount of P was quantified in the formulation. The simultaneous estimation of Fluticasone propionate and Azelastine hydrochloride in the formulation was reported by J. L. Bernal *et al.*, 1998; Murnane *et al.*, 2006; Nichole L. Korpi-Steiner., 2010; Sriram Krishnaswami., 2000). Since these methods were based on HPLC, Capillary electrophoresis, UV spectrophotometer and LC-MS/MS. Azelastine hydrochloride also with other combination drugs was appearing in the literature in human plasma (Pivonka J *et al.*, 1987).

References should be mentioned in the body text in parenthesis for e.g. (Murnane, 2006) not as numbers (1, 2, 3... or ¹, ², ³ ...) if more than two authors (Murnane *et al.*, 2006)

References should appear in the body text and follow Harvard system.

The chemical structures of Phenylethyl alcohol, Benzalkonium chloride, Fluticasone propionate and Azelastine Hydrochloride are shown in Fig. 1.

MATERIALS & METHODS

Reagents and chemicals

HPLC-grade acetonitrile and potassium dihydrogen ortho phosphate analytical grade were procured from Rankem (Mumbai, India) and pure standards of Phenylethyl alcohol (99.9%), Benzalkonium chloride (95.76%), Fluticasone propionate (98.95%) and Azelastine Hydrochloride (99.46%) was obtained from Dr. Reddy's Laboratories Ltd. HPLC grade water was prepared by using Millipore Milli Q plus purification system. The 0.45 μ m-nylon filter was obtained from Advanced Micro Devices Pvt. Ambala Cantt, India. Waters spherisorb CN column was procured from Waters Associates, Inc.

Instrumentation and Chromatographic Conditions

Chromatography was performed with a Agilent technologies 1100 LC (Germany), gradient pump with inbuilt auto injector, variable wavelength detector and Waters Alliance HPLC system (Milford, USA) equipped with a 2695 separation module with inbuilt auto injector and 2996 photodiode array detector. Waters Spherisorb CN column (250 x 4.6mm, 5- μ m particles) was used for chromatographic separation under suitable condition. Detection was carried out using a UV spectrophotometric detector at 215 nm and the software used was waters Empower2. The mobile phase was a 55:45 (v/v) mixture of freshly prepared buffer (50mM of potassium dihydrogen ortho phosphate) and acetonitrile. The mobile phase was sonicated and degassed before use. The diluent was mixture of water and acetonitrile in the ratio of 40:60 (v/v). The flow rate of mobile phase was maintained at 1.0 ml/min. The column temperature was maintained at ambient conditions. The injection volume was 20 μ L and total run time was 20 min. The peaks were identified by retention time; a typical chromatogram is shown in Fig. 2.

Mixed standard Preparation

Standard stock solution of AZH (1400 µg/ml), FLP (500 µg/ml) PEA (2500 µg/ml) and BKC (100 µg/ml) was prepared individually in diluent. 2.0ml of the each stock solution was pipetted out into 50ml volumetric flask and diluted to volume with diluent to achieve a final concentration of AZH (56.6µg/ml), FLP (19.8 µg/ml) PEA (100 µg/ml) and BKC (4 µg/ml). A system suitability test was performed for five replicate standard injections.

Sample preparation

Shaken and mixed the contents of 3 bottles (7ml each) in 100ml volumetric flask. Weighed accurately a quantity of nasal spray solution equivalent to 2ml into a 50ml volumetric flask. Added about 30ml diluent, sonicated for about 20minutes and then diluted to volume with diluent. Filtered through a 0.45µm nylon filter. A typical chromatogram obtained for a sample solution of assay is shown in Fig. 2.

RESULTS AND DISCUSSION

Method development

The objective of the study was to develop a simple, sensitive and specific method for the simultaneous determination of AZH, FLP, PEA and BKC in nasal spray formulation. The mobile phase was the mixture of acetonitrile with phosphate buffer in different ratios. Finally a mixture of acetonitrile-phosphate buffer in the ratio of 45:55 (v/v), proved to be effective mixture than the other mixture used for the separation. Then the flow rate tested includes 0.8, 1.0, 1.2 and 1.5 ml/min. Among the flow rates 1.0 ml/min was selected for the assay because of better visibility and resolution of the peaks. The final chromatographic conditions revealed to provide better resolution among Phenylethyl alcohol, Fluticasone propionate, Azelastine Hydrochloride and Benzalkonium chloride peaks i.e. greater than 2.0. Number of theoretical plates and tailing factor for each individual peak was more than 2000 and less than 2.0, respectively.

It is recommended that results should be presented in figures and tables along with a strong and suitable description in the text. Do not include landscape or long boring tables. Results should be structured.

The discussion should be concise and correlate with results, but don't repeat results. Put your results into perspective with previously published data. Include citation wherever applicable e.g. (Prakash, 2010)

b)

The optimum wavelength for detection was 215 nm, no indigenous interfering compounds eluted at the retention times of the drugs. Labeled amount of the drugs present in nasal spray preparations are given in Table.1.

Validation of the Method

The method was validated, in accordance with ICH guidelines (ICH Q2B), for precision, accuracy, linearity, specificity, ruggedness and robustness.

Linearity

Linearity was obtained in the concentration range 70.0 to 120.0 µg/mL for Phenylethyl alcohol, 14.0 to 24.0 µg/ml for Fluticasone propionate, 39.2 to 67.2 µg/ml for Azelastine Hydrochloride and in the range 2.8 to 4.8 µg/ml for Benzalkonium chloride. Linearity was performed with the aid of serially diluted calibration solutions from 70% to 120% of the target concentration. Calibration graphs were plotted on the basis of analysis of each calibration solutions. The coefficient of regression obtained was 0.9961, 0.9992, 0.997 and 0.9997, respectively for PEA, FLP, AZH and BKC. The slope obtained was 50988, 3883, 79373 and 854, respectively for PEA, FLP, AZH and BKC.

Precision and intermediate precision

The method was found to be precise with six sample preparations for the quantification of PEA, FLP, AZH and BKC. The precision was also studied on different day. The precision and intermediate precision variation was calculated in terms of percentage relative standard deviation and the results of PEA, FLP, AZH and BKC were found to be less than 2.0% and the results are given in Table. 1.

Accuracy

Accuracy was determined by the method of spiking the standard stock solution in placebo at six different levels, by multiple level recovery studies. Solution containing 2500 µg/ml PEA, 500 µg /ml FLP, 1400 µg/ml AZH and 100 µg/ml BKC standard stock solutions was prepared

and spiked with amounts of the standard drugs equivalent to 70, 80, 90, 100, 110 and 120% of the amounts present in the original solution. These solutions were then analyzed for recovery studies and the average recoveries ranged from 97% to 106%. Results for determination of accuracy are presented in Table 2 and 3.

Specificity

Placebo interference

Specificity was tested against standard compounds and against potential interferences in the presence of placebo. No interference was detected at the retention time of PEA, FLP, AZH and BKC (C12, C14) in placebo solution.

Forced degradation

The Forced degradation of placebo and formulation was carried out as per ICH guidelines (ICH, Q2B) in acid, base, oxidation and water. The acid, base, oxidation and water stress studies were carried out by refluxing sample & placebo into individual flasks at 60°C for half an hour with 10ml 0.1N HCl, 0.1N NaOH, 1% hydrogen peroxide and water respectively. The drug and the formulation were found to be stable under all the stress conditions. All the stress conditions with purity angle, purity threshold and purity flag results are reported in Table 4 to Table 8. Purity plots are shown in Fig. 3 to Fig. 7.

Solution stability

To demonstrate the stability of both standard and sample solutions during analysis, both solutions were analyzed over a period of 24 h at room temperature. The results showed that for all the solutions, the retention times and peak areas of PEA, FLP, AZH and BKC remained almost unchanged (RSD<2.0%) indicating that no significant degradation occurred within this period, i.e. both solutions were stable for at least 24 h, which was sufficient to complete the whole analytical process.

Ruggedness and Robustness

The ruggedness of the method was determined by using different instruments (Waters 2489).

The robustness of the method was determined by making slight changes in the chromatographic conditions ie organic phase composition $\pm 10\%$, flow rate ± 0.2 ml/min and column oven temperature $\pm 5^\circ\text{C}$. These results indicated that the method was rugged and robust with regard to these conditions. However, proper resolution also been achieved; separation of the drugs was very robust to the mobile phase ratio, flow rate and column oven temperature.

System suitability tests are an integral part of chromatographic method. They were used to verify that the reproducibility of the chromatographic system is adequate for the analysis. To ascertain its effectiveness, system suitability tests were carried out on freshly prepared standard stock solution of Phenylethyl alcohol, Fluticasone propionate, Azelastine Hydrochloride and Benzalkonium chloride. In addition, relative standard deviation of PEA, FLP, AZH and BKC peaks were evaluated by injecting mixed standard of the PEA, FLP, AZH and BKC (100, 20, 56.6 and 4.0 $\mu\text{g/ml}$).

Provide a clear scientific justification of your work. Do not repeat the abstract. Indicate possible application and extension.

Table 11.

CONCLUSION

The proposed RP-HPLC method for simultaneous assay of Phenylethyl alcohol, Fluticasone propionate, Azelastine Hydrochloride and Benzalkonium chloride in combined nasal spray preparations is simple, precise, specific, highly accurate and less time consumption for analysis could be recorded. So, it can definitely be employed for the routine and stability study analysis. Hence this RP-HPLC method is suitable for quality control of raw materials and formulations.

Acknowledgement section may be included if author wants to acknowledge to the research center, institution, organization, funding agency or to any scientist(s).

ACKNOWLEDGEMENTS

The authors are grateful to the Dr.Reddy's Laboratories Ltd. (Hyderabad, India) for gift samples (Phenylethyl alcohol, Fluticasone propionate, Azelastine Hydrochloride and Benzalkonium chloride) for providing laboratory facility for this research work.

REFERENCES

- Blanco M., D. methasone dipro squares regression
- British pharmacope
- ICH Q2B Validation
rence on Harmonisatio
for Human use, Genev
- Jadwiga Dudkiewicz-V
method for benzalkon
and Biomed Anal, 34(
- Louis-Philippe Labrar
Rapid determination o
tion. J. and Pharm and
- Lynn Laughler, Terry
An improved method
ma. J. of Pharm and B

Authors are responsible for the accuracy and completeness of the content including the list of references. References should appear at end of the article and should consist of the author name, surname and initial of authors, title of article, name of journal, year, volume, issue, first and last page numbers. Bulleted References list of complete citations are provided in alphabetical order. The Reference number should follow the following format. Examples are given below for more examples consider Author's Guidelines available at journal website www.ijrps.pharmascope.org

For journal reference

Prakash, KG, 1978. Floating drug delivery system. *International Journal of Research in Pharmaceutical Sciences*, 1(2), 12-24.

For Book reference

Lachman and Liberman, Theory and practice in Pharmacy, 2nd Edn, Vol 9, Lippincott Williams's publisher: 1995, 555 – 561.

For Chapters in book reference

P.S. Meltzer, A. Kallioniemi, and J.M. Trent. Chromosome alterations in human solid tumors. In: B. Vogelstein, and K.W. Kinzler (eds.), *The Genetic Basis of Human Cancer*, McGraw-Hill, New York, 2002, pp.93-113.

For Patent reference

H. Aviv, D. Friedman, A. Bar-Ilan, and M. Vered. Submicron emulsions as ocular drug delivery vehicles, U.S. Patent US 5496811, 1996.

For web reference

Young, C. English Heritage position statement on the Valletta Convention, [Online], Available: <http://www.archaeol.freeuk.com/EHPositionStatement.htm> [Accessed: 24 Aug 2001].

- Murnane D., G.P. Martin, C. Marriott. Validation of a reverse-phase high performance liquid chromatographic method for concurrent assay of a weak base (salmeterol xinafoate) and a pharmacologically active steroid (fluticasone propionate). *J. of Pharmaceutical and Biomedical Analysis*, 40(5), 2006, 1149-1154.
- Nichole L. Korpi-Steiner, Brian C. Netzel, Jesse C. Seegmiller, John B. Hagan, Ravinder J. Singh. Liquid chromatography–tandem mass spectrometry analysis of urinary fluticasone propionate-17beta-carboxylic acid for monitoring compliance with inhaled-fluticasone propionate therapy *Steroids*, 75(1), 2010, 77-82.

- Pivonka J., F. H. Segelman, C. A. Hartman, W. E. Segl, N. Kucharczyk, R. D. Sofia. Determination of azelastine and desmethylazelastine in human plasma by high-performance liquid chromatography. *J. of Chromatog: Biomed Applic*, 420, 1987, 89-98.
- Quantitation of active ingredients and excipients in nasal sprays by high-performance liquid chromatography, capillary electrophoresis and UV spectroscopy. *J. of Chromatog A*, 823(1-2), 1998, 423-431.
- Ramón Vargas, Robert J. Dockhorn, Steven R. Findlay, Phillip E. Korenblat, Elizabeth A. Field, Kenneth M. Kral. Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hypothalamic-pituitary-adrenal axis' *J. of Allergy and Clinical Immunology*, 102(2), 1998, 191-197.
- Sriram Krishnaswami, Helmut Möllmann, Hartmut Derendorf, Günther Hochhaus. A sensitive LC-MS/MS method for the quantification of fluticasone propionate in human plasma. *J. of Pharm and Biomed Anal*, 22(1), 2000, 123-129.
- The Merck Index – An Encyclopedia of chemicals, Drugs, and biologicals, 14 th edn, Merck Research Laboratories, Whitehouse station, NJ, 2006, pp 909, 1058, 4237, 7304.
- United states Pharmacopeia 32-NF27 Page 4129, 30-NF25 Page 1543, 30-NF25 Page 1069
- Ute Heinemann, Gottfried Blaschke, Norbert Knebel. Simultaneous enantioselective separation of azelastine and three of its metabolites for the investigation of the enantiomeric metabolism in rats: I. Liquid chromatography-ionspray tandem mass spectrometry and electrokinetic capillary chromatography. *J. of Chromatog B*, 793(2), 2003, 389-404.

Figures, Tables, images and other illustrations should be given at end of the manuscript with suitable caption and number.




Figure caption should be at the bottom. Not exceeding two lines or 20 words. Should be small letter starting from Figure 1:

Figure caption, Must be in the text form and should not be a part of the image

Figure 1: Chemical structures of Azelastine Hydrochloride

Images should be legible, sharp and should be 200dpi or higher resolution to fit A4 portrait not for landscape size page, JPEG, TIFF formats are preferred.




Figure 2: Typical chromatogram obtained from assay sample

Table caption should be on top. Not exceeding two lines or 20 words. Should be small letter starting from Table 1:

Table 1: Results from validation and system suitability studies of the method

Method characteristic	Phenyl ethyl alcohol	Fluticasone Propionate	Azelastine HCL	Benza - lkonium chloride (C12)	Benza- lkonium chloride (C14)
Theoretical plates	7810	7292	9342	12050	12598
Resolution	---	7.4	6.9	11.7	3.4
Tailing factor	1.6	1.5	1.7	1.5	1.3
% RSD for six injections	0.6	0.9	0.3	0.6	1.4
Accuracy (RSD(%))*	1.4	1.9	1.5	1.4***	
Precision (RSD(%))**	0.11	0.10	0.07	0.61***	
Intermediate Precision (RSD(%))**	0.04	0.05	0.06	1.36***	

* Results are mean of three sample preparations with six different drug concentration levels.

** Results are mean of six sample preparations.

***Results are mean of total area of benzalkonium chlor

Place abbreviations and footnotes immediately below the table

Table 2: Accuracy results of Phenylethyl alcohol and Fluticasone propionate in nasal spray preparations

% Spike level	Phenylethyl alcohol			Fluticasone propionate		
	µg/ml added	µg/ml found	% Avg recovery	µg/ml added	µg/ml found	% Avg recovery
70	70.0	70.9	101.3	13.9	13.9	99.8
80	80.0	82.8	103.6	15.8	16.1	102.2
90	90.0	93.1	103.5	17.8	18.4	103.2
100	100.0	102.8	102.8	19.8	20.7	104.4
110	110.0	111.9	101.7	21.8	23.0	105.4
120	120.0	120.1	100.1	23.8	24.9	104.6

Table should be prepared to fit A4 size portrait page not to fit landscape page. Table must be in text form not a part of image.

Table should be bordered in all sides of the cells without shading.